Ibuprofen modifies cognitive disease progression in an Alzheimer’s mouse model
Abstract
Prolonged use of non-steroidal anti-inflammatory drugs (NSAIDs) may reduce the risk of developing Alzheimer’s disease (AD) and delay disease onset. Negative results of clinical AD trials were rationalised by the discovery that certain NSAIDs reduce amyloid-β 1—42 (Aβ 1— 42 ) peptide production, the proposed central culprit in AD pathophysiology and main constituent of amyloid plaques, whereas other compounds do not affect Aβ levels. Latter observations motivated further in-vitro and in-vivo research regarding the applicability of NSAIDs in treating and/or preventing AD. We used the age-dependent cognitive decline in the APP23 transgenic mouse model for AD to evaluate disease-modifying efficacy of chronic ibuprofen treatment at the cognitive level. At age 6 weeks, heterozygous APP23 mice and control littermates were subcutaneously implanted with osmotic pumps delivering saline or ibuprofen (50 mg/kg daily). After 2 months of treatment, a 3-week washout period prevented bias from potential symptomatic effects before cognitive evaluation commenced. Ibuprofen-treated APP23 mice performed significantly better than their sham-treated counterparts and almost attained the same level of performance as control animals on a complex visual-spatial learning task. This study clearly reports disease-modifying efficacy of ibuprofen at the cognitive level in transgenic mice modelling AD.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Ibuprofen, as other NSAIDs, has demonstrated in in vivo studies the capability to delay the onset of AD.
“Ibuprofen (4), as other NSAIDs, has demonstrated in in vivo studies the capability to delay the onset of AD. 86”
From From combinations to multitarget-directed ligands: A continuum in Alzheimer’s disease polypharmacology (2021) · cites this paper as [86]
Cites
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514 · see citing works
Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology
Sturchler-Pierrat, C., Abramowski, D., Duke, M., Wiederhold, K.-H., Mistl, C., Rothacher, S., Ledermann, B., Bürki, K., Frey, P., Paganetti, P. A., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.24.13287 · Cited by 1,507 · see citing works
A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity
Weggen, S., Eriksen, J. L., Das, P., Sagi, S. A., Wang, R., Pietrzik, C. U., Findlay, K. A., Smith, T. E., Murphy, M. P., Bulter, T., et al. (2001) · Nature · doi:10.1038/35102591 · Cited by 1,388 · see citing works
Ibuprofen Suppresses Plaque Pathology and Inflammation in a Mouse Model for Alzheimer's Disease
Lim, G. P., Yang, F., Chu, T., Chen, P., Beech, W. K., Teter, B., Tran, T., Ubeda, O. J., Ashe, K. H., Frautschy, S. A., et al. (2000) · Journal of Neuroscience · doi:10.1523/jneurosci.20-15-05709.2000 · Cited by 876 · see citing works
NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo
Eriksen, J. L., Sagi, S. A., Smith, T. E., Weggen, S., Das, P., McLendon, D. C., Ozols, V. V., Jessing, K. W., Zavitz, K. H., Koo, E. H., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18162 · Cited by 634 · see citing works
Yan, Q., Zhang, J., Liu, H., Babu-Khan, S., Vassar, R., Biere, A. L., Citron, M., & Landreth, G. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-20-07504.2003 · Cited by 469 · see citing works
A randomized controlled trial of prednisone in Alzheimer’s disease
Aisen, P. S., Davis, K. L., Berg, J. D., Schafer, K., Campbell, K., Thomas, R. G., Weiner, M. F., Farlow, M. R., Sano, M., Grundman, M., et al. (2000) · Neurology · doi:10.1212/wnl.54.3.588 · Cited by 464 · see citing works
Sastre, M., Dewachter, I., Landreth, G. E., Willson, T. M., Klockgether, T., LEUVEN, F. V., & Heneka, M. T. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-30-09796.2003 · Cited by 359 · see citing works
Jantzen, P. T., Connor, K. E., DiCarlo, G., Wenk, G. L., Wallace, J. L., Rojiani, A. M., Coppola, D., Morgan, D., & Gordon, M. N. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-06-02246.2002 · Cited by 337 · see citing works
Nonsteroidal Anti-Inflammatory Drugs Can Lower Amyloidogenic Aß <sub>42</sub> by Inhibiting Rho
Zhou, Y., Su, Y., Li, B., Liu, F., Ryder, J. W., Wu, X., Gonzalez-DeWhitt, P. A., Gelfanova, V., Hale, J. E., May, P. C., et al. (2003) · Science · doi:10.1126/science.1090154 · Cited by 316 · see citing works
Age‐dependent cognitive decline in the APP23 model precedes amyloid deposition
Dam, D. V., D’Hooge, R., Staufenbiel, M., Ginneken, C. J. V., Meir, F. V., & Deyn, P. P. D. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02444.x · Cited by 297 · see citing works
Gasparini, L., Ongini, E., & Wenk, G. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02743.x · Cited by 226 · see citing works
Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice
Lim, G. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00299-8 · Cited by 224 · see citing works
Drug discovery in dementia: the role of rodent models
Dam, D. V., & Deyn, P. P. D. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2075 · Cited by 220 · see citing works
Kotilinek, L., Westerman, M. A., Wang, Q., Panizzon, K. L., Lim, G. P., Simonyi, Á., Lesné, S., Falinska, A. M., Younkin, L. H., Younkin, S. G., et al. (2008) · Brain · doi:10.1093/brain/awn008 · Cited by 220 · see citing works
van Gool, W. A., Weinstein, H. C., Scheltens, P., & Walstra, G. J. M. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05623-9 · Cited by 210 · see citing works
Nonsteroidal anti-inflammatory drugs lower Aβ42 and change presenilin 1 conformation
Lleó, A., Berezovska, O., Herl, L. D., Raju, S., Deng, A., Bacskai, B. J., Frosch, M. P., Irizarry, M. C., & Hyman, B. T. (2004) · Nature Medicine · doi:10.1038/nm1112 · Cited by 198 · see citing works
Progressive age-related impairment of cognitive behavior in APP23 transgenic mice
Kelly, P. H., Bondolfi, L., Hunziker, D., Schlecht, H. P., Carver, K., Maguire, E., Abramowski, D., Wiederhold, K., Sturchler, C., Jucker, M., et al. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00098-2 · Cited by 187 · see citing works
Pathogenic Mechanisms of Alzheimer's Disease Analyzed in the APP23 Transgenic Mouse Model
Sturchler, C., & Staufenbiel, M. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06915.x · Cited by 168 · see citing works
Berezovska, O., Lleó, A., Herl, L. D., Frosch, M. P., Stern, E. A., Bacskai, B. J., & Hyman, B. T. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.0364-05.2005 · Cited by 150 · see citing works
Hirohata, M., Ono, K., Naiki, H., & Yamada, M. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.07.004 · Cited by 131 · see citing works
Lalonde, R., Dumont, M., Staufenbiel, M., Sturchler, C., & Strazielle, C. (2002) · Brain Research · doi:10.1016/s0006-8993(02)03476-5 · Cited by 130 · see citing works
Dam, D. V., Abramowski, D., Staufenbiel, M., & Deyn, P. P. D. (2005) · Psychopharmacology · doi:10.1007/s00213-004-2132-z · Cited by 130 · see citing works
Weggen, S., Rogers, M. V., & Eriksen, J. L. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.09.004 · Cited by 124 · see citing works
Do NSAIDs prevent Alzheimer's disease? And, if so, why? The epidemiological evidence.
Zandi, P., & Breitner, J. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00297-4 · Cited by 112 · see citing works
Kuo, Y.-M., Beach, T. G., Sue, L. I., Scott, S., Layne, K. J., Kokjohn, T. A., Kalback, W. M., Luehrs, D. C., Vishnivetskaya, T. A., Abramowski, D., et al. (2001) · Molecular Medicine · doi:10.1007/bf03401867 · Cited by 90 · see citing works
Altered circadian locomotor activity in APP23 mice: a model for BPSD disturbances
Vloeberghs, E., Dam, D. V., Engelborghs, S., Nagels, G., Staufenbiel, M., & Deyn, P. P. D. (2004) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2004.03755.x · Cited by 79 · see citing works
Cognitive evaluation of disease-modifying efficacy of Galantamine and Memantine in the APP23 model
Dam, D. V., & Deyn, P. P. D. (2005) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.06.005 · Cited by 78 · see citing works
What Constitutes Clinical Evidence for Neuroprotection in Alzheimer Disease
Mori, E., Hashimoto, M., Krishnan, K., & Doraiswamy, P. M. (2006) · Alzheimer Disease & Associated Disorders · doi:10.1097/01.wad.0000213805.66811.31 · Cited by 47 · see citing works
Dam, D. V., Coen, K., & Deyn, P. P. D. (2007) · Psychopharmacology · doi:10.1007/s00213-007-1010-x · Cited by 44 · see citing works
Self-citationMeasuring behavior, mood, and psychiatric symptoms in Alzheimer disease.
Teri, L., Logsdon, R., & Yesavage, J. (1997) · PubMed · Cited by 39 · see citing works
Mood and male sexual behaviour in the APP23 model of Alzheimer's disease
Vloeberghs, E., Dam, D. V., Franck, F., Staufenbiel, M., & DEDEYN, P. (2007) · Behavioural Brain Research · doi:10.1016/j.bbr.2007.03.002 · Cited by 37 · see citing works
Self-citationBodick, N. C., Forette, F., Hadler, D., Harvey, R. J., Leber, P. D., McKeith, I. G., Riekkinen, P. J., Rossor, M. N., Scheltens, P., Shimohama, S., et al. (1997) · PubMed · Cited by 31 · see citing works
Aggressive male APP23 mice modeling behavioral alterations in dementia.
Vloeberghs, E., Dam, D. V., Coen, K., Staufenbiel, M., & Deyn, P. P. D. (2006) · Behavioral Neuroscience · doi:10.1037/0735-7044.120.6.1380 · Cited by 29 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy
McGeer, P. L., & McGeer, E. G. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1177-7 · Cited by 467 · see citing works
Inflammatory process in Alzheimer's Disease
Meraz-Ríos, M. A., Toral-Rios, D., Franco-Bocanegra, D., Villeda-Hernández, J., & Campos-Peña, V. (2013) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2013.00059 · Cited by 427 · see citing works
Animal models in the drug discovery pipeline for Alzheimer's disease
Dam, D. V., & Deyn, P. P. D. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01299.x · Cited by 228 · see citing works
Albertini, C., Salerno, A., de Sena Murteira Pinheiro, P., & Bolognesi, M. L. (2021) · Medicinal Research Reviews · doi:10.1002/med.21699 · Cited by 179 · see citing works
Parkinson, L., & Keast, R. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms150712323 · Cited by 156 · see citing works
Neuroinflammation in neurological disorders: pharmacotherapeutic targets from bench to bedside
Mishra, A., Bandopadhyay, R., Singh, P. K., Mishra, P. S., Sharma, N., & Khurana, N. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00806-4 · Cited by 132 · see citing works
Teter, B., Morihara, T., Lim, G. P., Chu, T., Jones, M. R., Zuo, X., Paul, R. M., Frautschy, S. A., & Cole, G. M. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.02.015 · Cited by 125 · see citing works
Tracking neuroinflammation in Alzheimer’s disease: the role of positron emission tomography imaging
Zimmer, E. R., Leuzy, A., Benedet, A. L., Breitner, J., Gauthier, S., & Rosa-Neto, P. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-120 · Cited by 121 · see citing works
An update on the efficacy of non-steroidal anti-inflammatory drugs in Alzheimer's disease
Imbimbo, B. P. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903066780 · Cited by 107 · see citing works
Microvascular Alterations in Alzheimer's Disease
Steinman, J., Sun, H., & Feng, Z. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.618986 · Cited by 82 · see citing works
You, M., Chen, Y., Pan, Y., Liu, Y.-C., Tu, J., Wang, K., & Hu, F. (2018) · Mediators of Inflammation · doi:10.1155/2018/7834381 · Cited by 73 · see citing works
Lee, D. C., Rizer, J., Hunt, J. B., Selenica, M. ‐. B., Gordon, M. N., & Morgan, D. (2013) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12002 · Cited by 57 · see citing works
Hong, Z., Shi, X., Zhu, K., Wu, T., & Zhu, Y. Z. (2014) · Journal of Neuroinflammation · doi:10.1186/s12974-014-0147-x · Cited by 50 · see citing works
Dailah, H. G. (2022) · Molecules · doi:10.3390/molecules27217207 · Cited by 50 · see citing works
Antiapoptotic Drugs: A Therapautic Strategy for the Prevention of Neurodegenerative Diseases
Sureda, F. X., Junyent, F., Verdaguer, E., Auladell, C., Pelegrı́, C., Vilaplana, J., Folch, J., Canudas, A. M., Zárate, C. B., Pallàs, M., et al. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211795049732 · Cited by 49 · see citing works
Genetic Mouse Models of Neurodegenerative Diseases
Trancikova, A. K., Ramonet, D., & Moore, D. J. (2011) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-384878-9.00012-1 · Cited by 46 · see citing works
Subacute ibuprofen treatment rescues the synaptic and cognitive deficits in advanced-aged mice
Rogers, J. T., Liu, C., Zhao, N., Wang, J., Putzke, T., Yang, L., Shinohara, M., Fryer, J. D., Kanekiyo, T., & Bu, G. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.02.001 · Cited by 39 · see citing works
Drug pipeline in neurodegeneration based on transgenic mice models of Alzheimer's disease
Li, C., Ebrahimi, A., & Schluesener, H. J. (2012) · Ageing Research Reviews · doi:10.1016/j.arr.2012.09.002 · Cited by 39 · see citing works
Neuroinflammatory Cytokines - The Common Thread in Alzheimer Pathogenesis
Griffin, W. S. T., Barger, S. W., & Chairman, D. P. A. V. (2011) · European Neurological Review · doi:10.17925/enr.2011.06.02.89 · Cited by 39 · see citing works
Systemic inflammation as a central player in the initiation and development of Alzheimer’s disease
Bayraktaroğlu, I., Ortí-Casañ, N., Dam, D. V., Deyn, P. P. D., & Eisel, U. L. M. (2025) · Immunity & Ageing · doi:10.1186/s12979-025-00529-5 · Cited by 42 · see citing works
Some Important Dietary Polyphenolic Compounds: An Anti-inflammatory and Immunoregulatory Perspective
Kinger, M., Kumar, S., & Kumar, V. (2017) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557517666170208143410 · Cited by 37 · see citing works
Gholizadeh, H., Ong, H. X., Bradbury, P., Kourmatzis, A., Traini, D., Young, P. M., Li, M., & Cheng, S. (2021) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2021.1873274 · Cited by 32 · see citing works
Current Disease-Targets for Oleocanthal as Promising Natural Therapeutic Agent
Segura‐Carretero, A., & Curiel, J. A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102899 · Cited by 31 · see citing works
Cerebroprotective effects of ibuprofen on diabetic encephalopathy in rats
Liu, Y., Zhu, X., Zhang, L., Lü, Q., Zhang, F., Guo, H., & Yin, X. (2013) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.11.027 · Cited by 29 · see citing works
Metcalf, C. S., Vanegas, F., Underwood, T. K., Johnson, K. J., West, P. J., Smith, M. D., & Wilcox, K. S. (2021) · Epilepsia Open · doi:10.1002/epi4.12550 · Cited by 29 · see citing works
Effects of Mediterranean Diet Components on Neurodegenerative Diseases
Farooqui, A. A., & Farooqui, T. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811959-4.00001-8 · Cited by 28 · see citing works
Gauging the role and impact of drug interactions and repurposing in neurodegenerative disorders
Khatri, D. K., Kadbhane, A., Patel, M., Nene, S., Atmakuri, S., Srivastava, S., & Singh, S. B. (2021) · Current Research in Pharmacology and Drug Discovery · doi:10.1016/j.crphar.2021.100022 · Cited by 24 · see citing works
Hsieh, K., Plascencia‐Villa, G., Lin, K., Perry, G. L., Jiang, X., & Kim, Y. (2022) · iScience · doi:10.1016/j.isci.2022.105678 · Cited by 24 · see citing works
Is it All Said for NSAIDs in Alzheimer’s Disease? Role of Mitochondrial Calcium Uptake
Sanz‐Blasco, S., Calvo-Rodríguez, M., Caballero, E., García-Durillo, M., Núñez, L., & Villalobos, C. (2017) · Current Alzheimer Research · doi:10.2174/1567205015666171227154016 · Cited by 23 · see citing works
Oleocanthal: A Naturally Occurring Anti-Inflammatory Agent in Virgin Olive Oil
Cicerale, S., J., L., & Keast, R. (2012) · InTech eBooks · doi:10.5772/28723 · Cited by 20 · see citing works
Ibuprofen in a Lipid Bilayer: Nanoscale Spatial Arrangement
Kashnik, A. S., Baranov, D. S., & Dzuba, S. A. (2022) · Membranes · doi:10.3390/membranes12111077 · Cited by 14 · see citing works
Synthesis of Spin-Labeled Ibuprofen and Its Interaction with Lipid Membranes
Baranov, D. S., Kashnik, A. S., & Dzuba, S. A. (2022) · Molecules · doi:10.3390/molecules27134127 · Cited by 13 · see citing works
Spatial Arrangement of the Drug Ibuprofen in a Model Membrane in the Presence of Lipid Rafts
Kashnik, A. S., Baranov, D. S., & Dzuba, S. A. (2024) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.4c01507 · Cited by 9 · see citing works
Targeting the awry Aβ pathway in Alzheimer’s disease: hype and hurdles
Al-Kuraishy, H. M., Sulaiman, G. M., Al-Gareeb, A. I., Mohammed, H. A., Albuhadily, A. K., & Abomughaid, M. M. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01983-9 · Cited by 8 · see citing works
Zhang, N.-Y., Wang, T., Chou, C.-H., Wu, K.-C., Yang, C., Kung, F., & Lin, C. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175256 · Cited by 8 · see citing works
Azzubaidi, M. S., & Al-Ani, I. M. D. (2020) · IIUM Medical Journal Malaysia · doi:10.31436/imjm.v18i2.93 · Cited by 6 · see citing works
Influence of Ibuprofen on glycerophospholipids and sphingolipids in context of Alzheimer´s Disease
Radermacher, J., Erhardt, V. K. J., Walzer, O., Haas, E. C., Kuppler, K. N., Zügner, J. S. R., Lauer, A. A., Hartmann, T., Grimm, H. S., & Grimm, M. O. W. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.117969 · Cited by 3 · see citing works
Ibuprofen in Prevention of Neurodegenerative Diseases
Rainsford, K. D. (2015) · doi:10.1002/9781118743614.ch14 · Cited by 2 · see citing works
Current and Prospective Treatments for Alzheimer's Disease (and Other Neurodegenerative Diseases)
Pedrini, S., Morici, M., & Martins, R. N. (2019) · Wiley eBooks · doi:10.1002/9781119356752.ch14 · Cited by 1 · see citing works
Dementias and Other Amnestic Disorders
Deyn, P. P. D., & Dam, D. V. (2014) · Springer eBooks · doi:10.1007/978-3-642-27772-6_247-2
Hsieh, K., Plascencia‐Villa, G., Lin, K., Perry, G. L., Jiang, X., & Kim, Y. (2022) · Research Square · doi:10.21203/rs.3.rs-1261984/v1
Dementias and Other Amnestic Disorders
Deyn, P. P. D., & Dam, D. V. (2015) · Springer eBooks · doi:10.1007/978-3-642-36172-2_247
Dementias and Other Amnestic Disorders
Deyn, P. P. D., & Dam, D. V. (2010) · Springer eBooks · doi:10.1007/978-3-540-68706-1_247
Alzheimer’s Disease and COVID-19 Pathogenic Overlap: Implications for Drug Repurposing
Golzari-Sorkheh, M., Liyanage, S. I., Reed, M. A., & Weaver, D. F. (2023) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2023.39
- Authors
- Van Dam, D., Coen, K., & De Deyn, P.
- Affiliations
- Laboratory of Neurochemistry and Behaviour, Institute Born-Bunge, University of Antwerp, Department of Biomedical Sciences, Wilrijk, Belgium
- University of Antwerp (BE)
- Laboratory of Neurochemistry and Behaviour, Institute Born-Bunge, University of Antwerp, Department of Biomedical Sciences, Wilrijk, Belgium, Department of Neurology/Memory clinic, Middelheim General Hospital, ZNA, Antwerp, Belgium,
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2008-10-28
- Volume
- 24
- Issue
- 3
- Pages
- 383-388
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2126470428
- Cited by
- 45
- References
- 34
- Citations by year
- 2025: 3 · 2024: 1 · 2023: 1 · 2022: 6 · 2021: 5 · 2020: 2 · 2019: 3 · 2018: 3 · 2017: 3 · 2015: 2 · 2014: 4 · 2013: 3 · 2012: 3
- FWCI
- 1.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology › Cholinesterase and Neurodegenerative Diseases
- Keywords
- ibuprofen, Alzheimer's disease, disease-modifying therapy, APP23 transgenic mice, cognitive decline, visual-spatial learning, amyloid-beta, nonsteroidal anti-inflammatory drugs, chronic drug administration, osmotic pump delivery
- MeSH terms
- Aging, Alzheimer Disease, Animals, Anti-Inflammatory Agents, Non-Steroidal, Cognition Disorders, Disease Models, Animal, Ibuprofen, Male, Mice, Inbred C57BL, Mice, Transgenic, Random Allocation, Infusion Pumps, Implantable, Disease Progression, Maze Learning, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
